1-5 of 5
Janis L. Abkowitz
Close
Sort by
Journal Articles

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

Clinical Trials & Observations
Anna B. Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A. Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Siobán B. Keel, Paul C. Hendrie, Bart L. Scott, M. Cristina Ghiuzeli, Elihu H. Estey, Roland B. Walter
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4950–4961.
https://doi.org/10.1182/bloodadvances.2023010392
Published: 2023
Journal Articles

The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolution

Raymond T. Doty, Christopher G. Lausted, Adam D. Munday, Zhantao Yang, Xiaowei Yan, Changting Meng, Qiang Tian, Janis L. Abkowitz
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4848–4868.
https://doi.org/10.1182/bloodadvances.2023010382
Published: 2023
Includes: Supplemental data
Journal Articles

ATG4A regulates human erythroid maturation and mitochondrial clearance

Massiel Chavez Stolla, Andreea Reilly, Rochelle Bergantinos, Sintra Stewart, Neele Thom, Courtnee A. Clough, Rachel C. Wellington, Raisa Stolitenko, Janis L. Abkowitz, Sergei Doulatov
Journal: Blood Advances
Blood Adv (2022) 6 (12): 3579–3589.
https://doi.org/10.1182/bloodadvances.2021005910
Published: 2022
Includes: Supplemental data
Journal Articles

Visualizing hematopoiesis as a stochastic process

Jason Xu, Yiwen Wang, Peter Guttorp, Janis L. Abkowitz
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2637–2645.
https://doi.org/10.1182/bloodadvances.2018023705
Published: 2018
Includes: Supplemental data
Journal Articles

Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies

Janis L. Abkowitz, Robert Hromas
Journal: Blood Advances
Blood Adv (2018) 2 (8): 846–847.
https://doi.org/10.1182/bloodadvances.2018017947
Published: 2018